Jacobs Levy Equity Management
CALA

Jacobs Levy Equity Management’s Calithera Biosciences, Inc CALA Stock Holding History

Jacobs Levy Equity Management’s Portfolio CALA Stock Details CALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-36,063
Closed -$480K – 1129
2021
Q4 		$480K Buy
36,063
+8,136
+29% +$204K ﹤0.01% 840
2021
Q3 		$1.22M Buy
27,927
+18,147
+186% +$783K 0.01% 715
2021
Q2 		$409K Sell
9,780
-1,744
-15% -$76.6K ﹤0.01% 900
2021
Q1 		$558K Sell
11,524
-93
-0.8% -$5.41K ﹤0.01% 848
2020
Q4 		$1.14M Sell
11,617
-932
-7% -$81.7K 0.01% 689
2020
Q3 		$866K Sell
12,549
-3,067
-20% -$268K 0.01% 691
2020
Q2 		$1.65M Buy
15,616
+3,537
+29% +$420K 0.02% 563
2020
Q1 		$1.07M Buy
12,079
+4,467
+59% +$532K 0.01% 604
2019
Q4 		$869K Buy
7,612
+5,321
+232% +$400K 0.01% 711
2019
Q3 		$142K Sell
2,291
-2,570
-53% -$206K ﹤0.01% 870
2019
Q2 		$379K Buy
4,861
+1,583
+48% +$180K 0.01% 783
2019
Q1 		$442K Sell
3,278
-245
-7% -$25.7K 0.01% 791
2018
Q4 		$283K Sell
3,523
-1,043
-23% -$103K 0.01% 818
2018
Q3 		$479K Buy
4,566
+255
+6% +$24.3K 0.01% 788
2018
Q2 		$431K Buy
4,311
+1,388
+47% +$157K 0.01% 829
2018
Q1 		$368K Buy
2,923
+1,995
+215% +$311K 0.01% 831
2017
Q4 		$155K Hold
928
– – ﹤0.01% 930
2017
Q3 		$292K Hold
928
– – 0.01% 796
2017
Q2 		$276K Sell
928
-238
-20% -$63.7K 0.01% 783
2017
Q1 		$269K Buy
1,166
+63
+6% +$10.9K 0.01% 741
2016
Q4 		$72K Buy
1,103
+275
+33% +$17.2K ﹤0.01% 925
2016
Q3 		$54K Hold
828
– – ﹤0.01% 990
2016
Q2 		$61K Sell
828
-1,092
-57% -$109K ﹤0.01% 1120
2016
Q1 		$218K Buy
+1,920
New +$218K ﹤0.01% 953

Other funds holding CALA

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Jacobs Levy Equity Management's CALA Position: Q1 2022 in Review

Jacobs Levy Equity Management sold out of Calithera Biosciences, Inc (CALA) in Q1 2022, closing a stake of 36,063 shares — an estimated $480K sold.

Jacobs Levy Equity Management first reported a position in CALA in Q1 2016 and held it in 24 quarters. The position peaked at $1.65M in Q2 2020. 54 funds tracked by Wall St. Rank hold CALA as of Q1 2022.

  • Jacobs Levy Equity Management reported no remaining Calithera Biosciences, Inc position as of Q1 2022 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 36,063 Calithera Biosciences, Inc shares in Q1 2022, an estimated $480K.
  • Jacobs Levy Equity Management first reported a position in Calithera Biosciences, Inc in Q1 2016 and held it in 24 quarters.
  • Jacobs Levy Equity Management's Calithera Biosciences, Inc position peaked at $1.65M in Q2 2020.
  • 54 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q1 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2022, filed 16 May 2022.